Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia

References

• Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17:13-27. doi:10.1016/j.ccr.2009.11.020. PMID:20060365
   PubMed Web of Science ®Google Scholar
• Hinoue T, Weisenberger DJ, Lange CP, Shen H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk CM, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012;22:271-82. doi:10.1101/gr.117523.110. PMID:21659424
   PubMed Web of Science ®Google Scholar
• Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tonjes M, Sill M, Bender S, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012;22:425-37. doi:10.1016/j.ccr.2012.08.024. PMID:23079654
   PubMed Web of Science ®Google Scholar
• CGARN. Cancer Genome Atlas Research Network: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059-74. doi:10.1056/NEJMoa1301689. PMID:23634996
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683-92. doi:10.1016/j.cell.2007.01.029. PMID:17320506
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148-59. doi:10.1056/NEJMra072067. PMID:18337604
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11:726-34. doi:10.1038/nrc3130. PMID:21941284
   PubMed Web of Science ®Google Scholar
• Saiki JH, McCredie KB, Vietti TJ, Hewlett JS, Morrison FS, Costanzi JJ, Stuckey WJ, Whitecar J, Hoogstraten B. 5-azacytidine in acute leukemia. Cancer. 1978;42:2111-4. doi:10.1002/1097-0142(197811)42:5. PMID:82472<2111::AID-CNCR2820420505>3.0.CO;2-I
   PubMed Web of Science ®Google Scholar
• Nervi C, De Marinis E, Codacci-Pisanelli G. Epigenetic treatment of solid tumours: A review of clinical trials. Clin Epigenetics. 2015;7:127. doi:10.1186/s13148-015-0157-2. PMID:26692909
   PubMed Web of Science ®Google Scholar
• Ghoshal K, Datta J, Majumder S, Bai S, Kutay H, Motiwala T, Jacob ST. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol. 2005;25:4727-41. doi:10.1128/MCB.25.11.4727-4741.2005. PMID:15899874
   PubMed Web of Science ®Google Scholar
• Stresemann C, Bokelmann I, Mahlknecht U, Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther. 2008;7:2998-3005. doi:10.1158/1535-7163.MCT-08-0411. PMID:18790780
   PubMed Web of Science ®Google Scholar
• Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM, Luebbert M. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;23:1019-28. doi:10.1038/leu.2008.397. PMID:19194470
   PubMed Web of Science ®Google Scholar
• Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007;6:1718-27. doi:10.1158/1535-7163.MCT-07-0010. PMID:17575103
   PubMed Web of Science ®Google Scholar
• Wodarz D, Boland CR, Goel A, Komarova NL. Methylation kinetics and CpG-island methylator phenotype status in colorectal cancer cell lines. Biol Direct. 2013;8:14. doi:10.1186/1745-6150-8-14. PMID:23758948
   PubMed Web of Science ®Google Scholar
• Cruijsen M, Luebbert M, Wijermans P, Huls G. Clinical results of hypomethylating agents in AML treatment. J Clin Med. 2014;4:1-17. doi:10.3390/jcm4010001. PMID:26237015
   PubMed Web of Science ®Google Scholar
• D'Alessio AC, Szyf M. Epigenetic tête-à-tête: The bilateral relationship between chromatin modifications and DNA methylation. Biochem Cell Biol. 2006;84:463-76. doi:10.1139/o06-090. PMID:16936820
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Chromatin modifications and their function. Cell. 2007;128:693-705. doi:10.1016/j.cell.2007.02.005. PMID:17320507
   PubMed Web of Science ®Google Scholar
• Momparler RL, Cote S, Momparler LF, Idaghdour Y. Epigenetic therapy of acute myeloid leukemia using 5-aza-2′-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation. Clin Epigenetics. 2014;6:19. doi:10.1186/1868-7083-6-19. PMID:25313314
   PubMed Web of Science ®Google Scholar
• Przybilla J, Rohlf T, Loeffler M, Galle J. Understanding epigenetic changes in aging stem cells–a computational model approach. Aging Cell. 2014;13:320-8. doi:10.1111/acel.12177. PMID:24428552
   PubMed Web of Science ®Google Scholar
• Hamidouche Z, Rother K, Przybilla J, Krinner A, Clay D, Hopp L, Fabian C, Stolzing A, Binder H, Charbord P, Galle, J. Bistable epigenetic states explain age-dependent decline in mesenchymal stem cell heterogeneity. Stem Cells. 2017 Mar;35(3):694-704. doi:10.1002/stem.2514. Epub 2016 Nov 8. PMID:27734598
   PubMed Web of Science ®Google Scholar
• Cui K, Zang C, Roh T-Y, Schones DE, Childs RW, Peng W, Zhao K. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell. 2009;4:80-93. doi:10.1016/j.stem.2008.11.011. PMID:19128795
   PubMed Web of Science ®Google Scholar
• Przybilla J, Buske P, Binder H, Galle J. Histone modifications control DNA methylation profiles during ageing and tumour expansion. Front Life Sci. 2013;7:31-43. doi:10.1080/21553769.2013.854279.
   Web of Science ®Google Scholar
• Przybilla J, Rohlf T, Galle J. Towards a mechanistic understanding of epigenetic dynamics. In: Teschendorff AE, editors. Computational and statistical epigenomics.. Springer; 2015. p. 141-60.
   Google Scholar
• Vermeulen M, Mulder KW, Denissov S, Pijnappel WW, van Schaik FM, Varier RA, Baltissen MP, Stunnenberg HG, Mann M, Timmers HT. Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4. Cell. 2007;131:58-69. doi:10.1016/j.cell.2007.08.016. PMID:17884155
   PubMed Web of Science ®Google Scholar
• Buratowski S, Kim T. The role of cotranscriptional histone methylations. Cold Spring Harb Symp Quant Biol. 2010;75:95-102. doi:10.1101/sqb.2010.75.036. PMID:21447819
   PubMedGoogle Scholar
• Pasini D, Malatesta M, Jung HR, Walfridsson J, Willer A, Olsson L, Skotte J, Wutz A, Porse B, Jensen ON, et al. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic Acids Res. 2010;38:4958-69. doi:10.1093/nar/gkq244. PMID:20385584
   PubMed Web of Science ®Google Scholar
• Jermann P, Hoerner L, Burger L, Schubeler D. Short sequences can efficiently recruit histone H3 lysine 27 trimethylation in the absence of enhancer activity and DNA methylation. Proc Natl Acad Sci U S A. 2014;111:E3415-21. doi:10.1073/pnas.1400672111. PMID:25092339
   PubMed Web of Science ®Google Scholar
• Thomson JP, Skene PJ, Selfridge J, Clouaire T, Guy J, Webb S, Kerr AR, Deaton A, Andrews R, James KD, et al. CpG islands influence chromatin structure via the CpG-binding protein Cfp1. Nature. 2010;464:1082-6. doi:10.1038/nature08924. PMID:20393567
   PubMed Web of Science ®Google Scholar
• Ooi SK, Qiu C, Bernstein E, Li K, Jia D, Yang Z, Erdjument-Bromage H, Tempst P, Lin SP, Allis CD, et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature. 2007;448:714-7. doi:10.1038/nature05987. PMID:17687327
   PubMed Web of Science ®Google Scholar
• Rush M, Appanah R, Lee S, Lam LL, Goyal P, Lorincz MC. Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation. Epigenetics. 2009;4:404-14. doi:10.4161/epi.4.6.9392. PMID:19717977
   PubMed Web of Science ®Google Scholar
• Binder H, Steiner L, Przybilla J, Rohlf T, Prohaska S, Galle J. Transcriptional regulation by histone modifications: Towards a theory of chromatin re-organization during stem cell differentiation. Phys Biol. 2013;10:026006. doi:10.1088/1478-3975/10/2/026006. PMID:23481318
   PubMed Web of Science ®Google Scholar
• Schnerch D, Yalcintepe J, Schmidts A, Becker H, Follo M, Engelhardt M, Wasch R. Cell cycle control in acute myeloid leukemia. Am J Cancer Res. 2012;2:508-28. PMID:22957304
   PubMed Web of Science ®Google Scholar
• Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, Boyiadzis M. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: Associations with prognosis and potential treatment strategies. Leukemia. 2014;28:1774-83. doi:10.1038/leu.2014.124. PMID:24699305
   PubMed Web of Science ®Google Scholar
• Huang G, Zhao X, Wang L, Elf S, Xu H, Sashida G, Zhang Y, Liu Y, Lee J, Menendez S, et al. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood. 2011;118:6544-52. doi:10.1182/blood-2010-11-317909. PMID:22012064
   PubMed Web of Science ®Google Scholar
• Prasad P, Ronnerblad M, Arner E, Itoh M, Kawaji H, Lassmann T, Daub CO, Forrest AR, Lennartsson A, Ekwall K. High-throughput transcription profiling identifies putative epigenetic regulators of hematopoiesis. Blood. 2014;123:e46-57. doi:10.1182/blood-2013-02-483537. PMID:24671951
   PubMed Web of Science ®Google Scholar
• Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A. 2012;109:5028-33. doi:10.1073/pnas.1202258109. PMID:22396593
   PubMed Web of Science ®Google Scholar
• Preisler HD, Raza A, Gopal V, Ahmad S, Bokhari J. Distribution of cell cycle times amongst the leukemia cells within individual patients with acute myelogenous leukemia. Leuk Res. 1995;19:693-8. doi:10.1016/0145-2126(95)98846-P. PMID:7500644
   PubMed Web of Science ®Google Scholar
• Weirich S, Kudithipudi S, Jeltsch A. Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex. Mol Oncol. 2017;11:373-87. doi:10.1002/1878-0261.12041. PMID:28182322
   PubMed Web of Science ®Google Scholar
• Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med. 2016;22:792-9. doi:10.1038/nm.4125. PMID:27322744
   PubMed Web of Science ®Google Scholar
• Jiang X, Lim CZ, Li Z, Lee PL, Yatim SM, Guan P, Li J, Zhou J, Pan J, Chng WJ, et al. Functional characterization of D9, a novel deazaneplanocin A (DZNep) Analog, in targeting acute myeloid leukemia (AML). PLoS One. 2015;10:e0122983. doi:10.1371/journal.pone.0122983. PMID:25928216
   PubMed Web of Science ®Google Scholar
• Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla KN. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia. 2014;28:2155-64. doi:10.1038/leu.2014.119. PMID:24699304
   PubMed Web of Science ®Google Scholar
• Ramos MP, Wijetunga NA, McLellan AS, Suzuki M, Greally JM. DNA demethylation by 5-aza-2′-deoxycytidine is imprinted, targeted to euchromatin, and has limited transcriptional consequences. Epigenetics Chromatin. 2015;8:11. doi:10.1186/s13072-015-0004-x. PMID:25806086
   PubMed Web of Science ®Google Scholar
• Li LH, Olin EJ, Buskirk HH, Reineke LM. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res. 1970;30:2760-9. PMID:5487063
   PubMed Web of Science ®Google Scholar
• Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: Results of the US Leukemia Intergroup trial E1905. J Clin Oncol. 2014;32:1242-8. doi:10.1200/JCO.2013.50.3102. PMID:24663049
   PubMed Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A. 2010;107:7473-8. doi:10.1073/pnas.1002650107. PMID:20368434
   PubMed Web of Science ®Google Scholar
• Grishina O, Schmoor C, Dohner K, Hackanson B, Lubrich B, May AM, Cieslik C, Mueller MJ, Luebbert M. DECIDER: Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy. BMC Cancer. 2015;15:430. doi:10.1186/s12885-015-1432-5.. PMID:26008690
   PubMed Web of Science ®Google Scholar
• Loffler-Wirth H, Kalcher M, Binder H. oposSOM: R-package for high-dimensional portraying of genome-wide expression landscapes on bioconductor. Bioinformatics. 2015;31:3225-7. doi:10.1093/bioinformatics/btv342. PMID:26063839
   PubMed Web of Science ®Google Scholar
• Schoofs T, Berdel WE, Muller-Tidow C. Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia. 2014;28:1-14. doi:10.1038/leu.2013.242. PMID:23958917
   PubMed Web of Science ®Google Scholar
• Oittinen M, Popp A, Kurppa K, Lindfors K, Mäki M, Kaikkonen MU, Viiri K. Polycomb Repressive Complex 2 Enacts Wnt Signaling in Intestinal Homeostasis and Contributes to the Instigation of Stemness in Diseases Entailing Epithelial Hyperplasia or Neoplasia. Stem Cells. 2017 Feb;32(2):445–457. doi:10.1002/stem.2479. Epub 2016 Sep 13
   Web of Science ®Google Scholar
• Uy GL, Duncavage EJ, Chang GS, Jacoby MA, Miller CA, Shao J, Heath S, Elliott K, Reineck T, Fulton RS, Fronick CC, O'Laughlin M, Ganel L, Abboud CN, Cashen AF, DiPersio JF, Wilson RK, Link DC, Welch JS, Ley TJ, Graubert TA, Westervelt P, Walter MJ. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia. 2017 Apr;31(4):872–881. doi:10.1038/leu.2016.282. Epub 2016 Oct 14. PMID:27740633
   PubMed Web of Science ®Google Scholar
• Licht JD. DNA methylation inhibitors in cancer therapy: The immunity dimension. Cell. 2015;162:938-9. doi:10.1016/j.cell.2015.08.005. PMID:26317460
   PubMed Web of Science ®Google Scholar
• Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015;162:974-86. doi:10.1016/j.cell.2015.07.011. PMID:26317466
   PubMed Web of Science ®Google Scholar
• Spencer DH, Russler-Germain DA, Ketkar S, Helton NM, Lamprecht TL, Fulton RS, Fronick CC, O'Laughlin M, Heath SE, Shinawi M, et al. CpG island hypermethylation mediated by DNMT3A is a consequence of AML progression. Cell. 2017;168:801-16 e13. doi:10.1016/j.cell.2017.01.021. PMID:28215704
   PubMed Web of Science ®Google Scholar
• Drolle H, Wagner M, Vasold J, Kutt A, Deniffel C, Sotlar K, Sironi S, Herold T, Rieger C, Fiegl M. Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy. Leuk Res. 2015;39:779-85. doi:10.1016/j.leukres.2015.04.019. PMID:25982178
   PubMed Web of Science ®Google Scholar
• Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: Functional insights and clinical implications. Nat Med. 2006;12:1181-4. doi:10.1038/nm1487. PMID:17013383
   PubMed Web of Science ®Google Scholar
• Horn M, Glauche I, Muller MC, Hehlmann R, Hochhaus A, Loeffler M, Roeder I. Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood. 2013;121:378-84. doi:10.1182/blood-2012-07-441956. PMID:23175686
   PubMed Web of Science ®Google Scholar